We are live on ! Find out more
ROIV icon

Roivant Sciences

318 hedge funds and large institutions have $6.65B invested in Roivant Sciences in 2024 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 94 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 41

9% more funds holding

Funds holding: 293318 (+25)

1% more capital invested

Capital invested by funds: $6.57B → $6.65B (+$86.7M)

0.32% more ownership

Funds ownership: 76.97%77.28% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 1717 (0)

9% less repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 103

14% less call options, than puts

Call options by funds: $9.58M | Put options by funds: $11.1M

Holders
318
Holders Change
+25
Holders Change %
+8.53%
% of All Funds
4.19%
Holding in Top 10
17
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.22%
New
69
Increased
94
Reduced
103
Closed
41
Calls
$9.58M
Puts
$11.1M
Net Calls
-$1.53M
Net Calls Change
+$14.2M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
26
Pertento Partners
United Kingdom
$41.2M +$7.65M +646,865 +23%
Northern Trust
27
Northern Trust
Illinois
$40.8M +$7.72M +652,615 +23%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$40.7M +$6.03M +510,398 +17%
PC
29
PointState Capital
New York
$39M -$9.58M -810,403 -20%
N
30
Nuveen
North Carolina
$35.7M -$2.03M -171,939 -5%
Marshall Wace
31
Marshall Wace
United Kingdom
$34.9M +$17.8M +1,505,062 +104%
Charles Schwab
32
Charles Schwab
California
$33.3M +$533K +45,090 +2%
SC
33
Stempoint Capital
New York
$32.1M -$674K -57,041 -2%
First Trust Advisors
34
First Trust Advisors
Illinois
$28.9M -$6.64M -561,219 -19%
UBS AM
35
UBS AM
Illinois
$28.5M +$1.23M +104,288 +5%
WCM
36
Whitefort Capital Management
New York
$28.3M
Goldman Sachs
37
Goldman Sachs
New York
$24.9M -$38.8M -3,283,753 -61%
TCM
38
Tyro Capital Management
Florida
$24.9M +$4.18M +353,307 +20%
Impax Asset Management Group
39
Impax Asset Management Group
United Kingdom
$23.7M
ClearBridge Investments
40
ClearBridge Investments
New York
$22M +$47 +4 +0%
Citadel Advisors
41
Citadel Advisors
Florida
$21.4M -$48.8M -4,123,404 -70%
Bank of America
42
Bank of America
North Carolina
$20.3M -$4.91M -415,363 -19%
PDM
43
Penn Davis McFarland
Texas
$19.5M +$199K +16,832 +1%
PM
44
Prosight Management
Texas
$17.7M -$2.62M -221,512 -13%
RI
45
RTW Investments
New York
$17.2M
VPC
46
Vestal Point Capital
New York
$14.8M +$14.8M +1,250,000 New
GGHC
47
Gilder Gagnon Howe & Co
New York
$13.8M +$13.7M +1,162,986 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$12.7M -$136K -11,498 -1%
Principal Financial Group
49
Principal Financial Group
Iowa
$11.6M -$298K -25,239 -2%
Pictet Asset Management
50
Pictet Asset Management
Switzerland
$11M -$2.07M -175,418 -16%

ROIV Hedge Fund Activity: Q4 2024 in Review

318 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q4 2024, worth a combined $6.65B — up 1.3% from $6.57B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new ROIV positions and 41 closed out — a net gain of 28 holders — while 94 added to existing stakes and 103 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $58.4M. The largest seller was Viking Global Investors, cutting an estimated $74.4M.

  • 318 institutional investors held Roivant Sciences (ROIV) as of Q4 2024, up from 293 in Q3 2024.
  • Funds reported $6.65B of Roivant Sciences stock for Q4 2024, up 1.3% quarter-over-quarter.
  • 69 funds opened new Roivant Sciences positions in Q4 2024 and 41 closed out, a net change of +28 holders.
  • The largest Roivant Sciences buyer in Q4 2024 was Morgan Stanley, an estimated $58.4M added.
  • The largest Roivant Sciences seller in Q4 2024 was Viking Global Investors, an estimated $74.4M sold.

Based on aggregated 13F filings for Q4 2024.